The segment has immense growth potential driven by the country's increasing healthcare needs, technological innovations, government support, and emerging market opportunities
Harnessing advanced data analysis for early detection, prevention and better outcomes
First and only PARP inhibitor to improve overall survival in early breast cancer
Aims to become India’s leading cancer testing company
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
CPHI & PMEC India Expo 2024 to bring over 50,000 industry professionals and 2,000 exhibitors under one roof
HYMPAVZI’s approval is based on Phase 3 study results demonstrating non-inferiority and superiority compared to routine prophylaxis in eligible patients with hemophilia A or B without inhibitors
Modernization and supply chain diversity drive new growth
Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years
The centre is equipped with the most modern tools and provides an environment soothing for all professionals and patients
Subscribe To Our Newsletter & Stay Updated
